E

A potential new IO combination for clinical development

People love hearing about new or emerging cancer targets - there's always the hope that one might find something cool that could move the needle and really make a difference...

December 8, 2017
E

IMpower150 lung cancer trial provides a window to the Future of Immunotherapy

The first phase 3 trial in 1L NSCLC to hit the PFS endpoint is Genentech's IMpower150. What can we learn from this study?

December 7, 2017